Literature DB >> 16985262

PPAR{alpha} mediates the hypolipidemic action of fibrates by antagonizing FoxO1.

Shen Qu1, Dongming Su, Jennifer Altomonte, Adama Kamagate, Jing He, German Perdomo, Tonia Tse, Yu Jiang, H Henry Dong.   

Abstract

High-fructose consumption is associated with insulin resistance and diabetic dyslipidemia, but the underlying mechanism is unclear. We show in hamsters that high-fructose feeding stimulated forkhead box O1 (FoxO1) production and promoted its nuclear redistribution in liver, correlating with augmented apolipoprotein C-III (apoC-III) production and impaired triglyceride metabolism. High-fructose feeding upregulated peroxisome proliferator-activated receptor-gamma coactivator-1beta and sterol regulatory element binding protein-1c expression, accounting for increased fat infiltration in liver. High-fructose-fed hamsters developed hypertriglyceridemia, accompanied by hyperinsulinemia and glucose intolerance. These metabolic aberrations were reversible by fenofibrate, a commonly used anti-hypertriglyceridemia agent that is known to bind and activate peroxisome proliferator-activated receptor-alpha (PPARalpha). PPARalpha physically interacted with, but functionally antagonized, FoxO1 in hepatic apoC-III expression. These data underscore the importance of FoxO1 deregulation in the pathogenesis of hypertriglyceridemia in high-fructose-fed hamsters. Counterregulation of hepatic FoxO1 activity by PPARalpha constitutes an important mechanism by which fibrates act to curb apoC-III overproduction and ameliorate hypertriglyceridemia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16985262      PMCID: PMC2665003          DOI: 10.1152/ajpendo.00157.2006

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  54 in total

1.  Differential regulation of gene expression by insulin and IGF-1 receptors correlates with phosphorylation of a single amino acid residue in the forkhead transcription factor FKHR.

Authors:  J Nakae; V Barr; D Accili
Journal:  EMBO J       Date:  2000-03-01       Impact factor: 11.598

2.  A potent PPARalpha agonist stimulates mitochondrial fatty acid beta-oxidation in liver and skeletal muscle.

Authors:  A Minnich; N Tian; L Byan; G Bilder
Journal:  Am J Physiol Endocrinol Metab       Date:  2001-02       Impact factor: 4.310

3.  Targeting foxo1 in mice using antisense oligonucleotide improves hepatic and peripheral insulin action.

Authors:  Varman T Samuel; Cheol Soo Choi; Trevor G Phillips; Anthony J Romanelli; John G Geisler; Sanjay Bhanot; Robert McKay; Brett Monia; John R Shutter; Richard A Lindberg; Gerald I Shulman; Murielle M Veniant
Journal:  Diabetes       Date:  2006-07       Impact factor: 9.461

4.  Effect of rosuvastatin on hepatic production of apolipoprotein B-containing lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia.

Authors:  Taryne Chong; Mark Naples; Lisa Federico; Denise Taylor; Graham J Smith; Raphael C Cheung; Khosrow Adeli
Journal:  Atherosclerosis       Date:  2005-07-05       Impact factor: 5.162

5.  Aberrant Forkhead box O1 function is associated with impaired hepatic metabolism.

Authors:  Shen Qu; Jennifer Altomonte; German Perdomo; Jing He; Yong Fan; Adama Kamagate; Marcia Meseck; H Henry Dong
Journal:  Endocrinology       Date:  2006-09-21       Impact factor: 4.736

6.  Hyperlipidemic effects of dietary saturated fats mediated through PGC-1beta coactivation of SREBP.

Authors:  Jiandie Lin; Ruojing Yang; Paul T Tarr; Pei-Hsuan Wu; Christoph Handschin; Siming Li; Wenli Yang; Liming Pei; Marc Uldry; Peter Tontonoz; Christopher B Newgard; Bruce M Spiegelman
Journal:  Cell       Date:  2005-01-28       Impact factor: 41.582

Review 7.  The insulin resistance syndrome: impact on lipoprotein metabolism and atherothrombosis.

Authors:  H N Ginsberg; L S Huang
Journal:  J Cardiovasc Risk       Date:  2000-10

8.  Dual role of transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid metabolism.

Authors:  Michihiro Matsumoto; Seongah Han; Tadahiro Kitamura; Domenico Accili
Journal:  J Clin Invest       Date:  2006-08-10       Impact factor: 14.808

9.  Intestinal lipoprotein overproduction, a newly recognized component of insulin resistance, is ameliorated by the insulin sensitizer rosiglitazone: studies in the fructose-fed Syrian golden hamster.

Authors:  Gary F Lewis; Kristine Uffelman; Mark Naples; Linda Szeto; Mehran Haidari; Khosrow Adeli
Journal:  Endocrinology       Date:  2004-10-14       Impact factor: 4.736

10.  The hypolipidemic action of bezafibrate therapy in hypertriglyceridemia is mediated by upregulation of lipoprotein lipase: no effects on VLDL substrate affinity to lipolysis or LDL receptor binding.

Authors:  F H de Man; F de Beer; A van der Laarse; H Jansen; J A Leuven; J H Souverijn; T F Vroom; S C Schoormans; J C Fruchart; L M Havekes; A H Smelt
Journal:  Atherosclerosis       Date:  2000-12       Impact factor: 5.162

View more
  44 in total

1.  FoxO1 links hepatic insulin action to endoplasmic reticulum stress.

Authors:  Adama Kamagate; Dae Hyun Kim; Ting Zhang; Sandra Slusher; Roberto Gramignoli; Stephen C Strom; Suzanne Bertera; Steven Ringquist; H Henry Dong
Journal:  Endocrinology       Date:  2010-05-25       Impact factor: 4.736

2.  FoxO1 and hepatic lipid metabolism.

Authors:  Janet D Sparks; Henry H Dong
Journal:  Curr Opin Lipidol       Date:  2009-06       Impact factor: 4.776

3.  Adrenoceptor-related decrease in serum triglycerides is independent of PPARα activation.

Authors:  Maria Konstandi; Kyriakos E Kypreos; Tsutomu Matsubara; Eva Xepapadaki; Yatrik M Shah; Kristopher Krausz; Christina E Andriopoulou; Aristeidis Kofinas; Frank J Gonzalez
Journal:  FEBS J       Date:  2019-06-28       Impact factor: 5.542

4.  Aberrant expression of microRNA induced by high-fructose diet: implications in the pathogenesis of hyperlipidemia and hepatic insulin resistance.

Authors:  Neetu Sud; Hanyuan Zhang; Kaichao Pan; Xiao Cheng; Juan Cui; Qiaozhu Su
Journal:  J Nutr Biochem       Date:  2017-02-20       Impact factor: 6.048

5.  FoxO1 Plays an Important Role in Regulating β-Cell Compensation for Insulin Resistance in Male Mice.

Authors:  Ting Zhang; Dae Hyun Kim; Xiangwei Xiao; Sojin Lee; Zhenwei Gong; Radhika Muzumdar; Virtu Calabuig-Navarro; Jun Yamauchi; Hideyoshi Harashima; Rennian Wang; Rita Bottino; Juan Carlos Alvarez-Perez; Adolfo Garcia-Ocaña; George Gittes; H Henry Dong
Journal:  Endocrinology       Date:  2016-01-04       Impact factor: 4.736

6.  Aberrant Forkhead box O1 function is associated with impaired hepatic metabolism.

Authors:  Shen Qu; Jennifer Altomonte; German Perdomo; Jing He; Yong Fan; Adama Kamagate; Marcia Meseck; H Henry Dong
Journal:  Endocrinology       Date:  2006-09-21       Impact factor: 4.736

7.  ATF4 protein deficiency protects against high fructose-induced hypertriglyceridemia in mice.

Authors:  Guozhi Xiao; Ting Zhang; Shibing Yu; Sojin Lee; Virtu Calabuig-Navarro; Jun Yamauchi; Steven Ringquist; H Henry Dong
Journal:  J Biol Chem       Date:  2013-07-25       Impact factor: 5.157

8.  Diabetic dyslipidemia and atherosclerosis: evidence from clinical trials.

Authors:  John A Farmer
Journal:  Curr Atheroscler Rep       Date:  2007-08       Impact factor: 5.113

9.  Peroxisome proliferator-activated receptor alpha target genes.

Authors:  Maryam Rakhshandehroo; Bianca Knoch; Michael Müller; Sander Kersten
Journal:  PPAR Res       Date:  2010-09-26       Impact factor: 4.964

10.  New metabolites of fenofibrate in Sprague-Dawley rats by UPLC-ESI-QTOF-MS-based metabolomics coupled with LC-MS/MS.

Authors:  A Liu; Y Chen; Z Yang; Y Feng; W Rui; W Luo; Y Liu; F J Gonzalez; R Dai
Journal:  Xenobiotica       Date:  2009-04       Impact factor: 1.908

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.